Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104566 · ClinicalTrials.gov registry record · Phase 3
Global Trial in APG2575 for Patients With CLL/SLL
A Phase 3 study of CLL/SLL, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 2
- Study locations
NCT06104566 is a Phase 3 study of CLL/SLL that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 400 participants, above the 59-participant average among 5 other CLL/SLL trials with a reported enrollment target (578% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06104566, a Phase 3 study of CLL/SLL, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Conditions Studied
Interventions
- DRUG lisaftoclax +BTK inhibitor
- DRUG BTK inhibitor
Study Locations (2)
Texas
- MD Anderson Cancer Center - Houston
Other
- Kaluga Regional Clinical Research - Kaluga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104566
The ClinicalTrials.gov registry entry for NCT06104566 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 5 other CLL/SLL trials with a reported enrollment target (578% higher). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CLL/SLL appearing as the primary indexed condition, and to 2 interventions - of which lisaftoclax +BTK inhibitor is the first listed.
NCT06104566 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06104566 about?
NCT06104566 is a clinical study titled "Global Trial in APG2575 for Patients With CLL/SLL". This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
What is the current status of trial NCT06104566?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2023-12-20. Estimated completion is 2027-10-31.
What conditions does trial NCT06104566 study?
This clinical trial studies the following conditions: CLL/SLL.
What interventions are being tested in trial NCT06104566?
The interventions under investigation include: lisaftoclax +BTK inhibitor (DRUG), BTK inhibitor (DRUG).
Who is sponsoring clinical trial NCT06104566?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104566 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL/SLL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
RECRUITING · Phase 2
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
RECRUITING · Phase 1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RECRUITING · Phase 1
-
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
RECRUITING · Phase 2
-
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.